Does denosumab exert a protective effect against COVID-19? Results of a large cohort study
ConclusionOur study confirms that denosumab may be safely continued in COVID-19 patients. RANK/RANKL inhibition seems associated with a reduced incidence of symptomatic COVID-19, particularly among the elderly.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Coronavirus | COVID-19 | Endocrinology | Smokers | Statistics | Study | Vitamin D | Vitamins | Xgeva